Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features

Anna Guadall; Elodie Lesteven; Gil Letort; Sarah Awan Toor; Marc Delord; Doriane Pognant; Mégane Brusson; Emmanuelle Verger; Nabih Maslah; Stéphane Giraudier; Jerome Larghero; Valerie Vanneaux; Christine Chomienne; Wassim El Nemer; Bruno Cassinat; Jean-Jacques Kiladjian

doi:10.1055/s-0038-1667015

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2018; 118(09): 1586-1599
DOI: 10.1055/s-0038-1667015

Endothelium and Angiogenesis

Georg Thieme Verlag KG Stuttgart · New York

Endothelial Cells Harbouring the JAK2^V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features

Authors

Anna Guadall^*

¹INSERM, UMRS_1131, Institut Universitaire d'Hématologie, Université Paris-Diderot, Hopital Saint-Louis, Paris, France
Elodie Lesteven^*

¹INSERM, UMRS_1131, Institut Universitaire d'Hématologie, Université Paris-Diderot, Hopital Saint-Louis, Paris, France
Gil Letort

¹INSERM, UMRS_1131, Institut Universitaire d'Hématologie, Université Paris-Diderot, Hopital Saint-Louis, Paris, France
Sarah Awan Toor

¹INSERM, UMRS_1131, Institut Universitaire d'Hématologie, Université Paris-Diderot, Hopital Saint-Louis, Paris, France
Marc Delord

²Bioinformatique, Institut Universitaire d'Hématologie, Université Paris-Diderot, Hopital Saint-Louis, Paris, France
Doriane Pognant

¹INSERM, UMRS_1131, Institut Universitaire d'Hématologie, Université Paris-Diderot, Hopital Saint-Louis, Paris, France
Mégane Brusson

³INSERM, INTS, Unité Biologie Intégrée du Globule Rouge, Paris, France
Emmanuelle Verger

¹INSERM, UMRS_1131, Institut Universitaire d'Hématologie, Université Paris-Diderot, Hopital Saint-Louis, Paris, France

⁴APHP, Laboratoire de Biologie Cellulaire, Hopital Saint-Louis, Paris, France
Nabih Maslah

¹INSERM, UMRS_1131, Institut Universitaire d'Hématologie, Université Paris-Diderot, Hopital Saint-Louis, Paris, France

⁴APHP, Laboratoire de Biologie Cellulaire, Hopital Saint-Louis, Paris, France
Stéphane Giraudier

¹INSERM, UMRS_1131, Institut Universitaire d'Hématologie, Université Paris-Diderot, Hopital Saint-Louis, Paris, France

⁴APHP, Laboratoire de Biologie Cellulaire, Hopital Saint-Louis, Paris, France

⁵Universite Paris Diderot, Paris, France
Jerome Larghero

⁶APHP, Laboratoire de Therapie Cellulaire, Hopital Saint-Louis, Paris, France
Valerie Vanneaux

⁶APHP, Laboratoire de Therapie Cellulaire, Hopital Saint-Louis, Paris, France
Christine Chomienne

¹INSERM, UMRS_1131, Institut Universitaire d'Hématologie, Université Paris-Diderot, Hopital Saint-Louis, Paris, France

⁴APHP, Laboratoire de Biologie Cellulaire, Hopital Saint-Louis, Paris, France

⁵Universite Paris Diderot, Paris, France
Wassim El Nemer

³INSERM, INTS, Unité Biologie Intégrée du Globule Rouge, Paris, France
Bruno Cassinat

¹INSERM, UMRS_1131, Institut Universitaire d'Hématologie, Université Paris-Diderot, Hopital Saint-Louis, Paris, France

⁴APHP, Laboratoire de Biologie Cellulaire, Hopital Saint-Louis, Paris, France
Jean-Jacques Kiladjian^**

¹INSERM, UMRS_1131, Institut Universitaire d'Hématologie, Université Paris-Diderot, Hopital Saint-Louis, Paris, France

⁵Universite Paris Diderot, Paris, France

⁷APHP, Centre d'Investigations Cliniques, Hopital Saint-Louis, Paris, France

Abstract

Thromboembolic events are the main cause of mortality in BCR-ABL1-negative myeloproliferative neoplasms (MPNs) but their underlying mechanisms are largely unrecognized. The Janus kinase 2 (JAK2)^V617F mutation is the most frequent genetic alteration leading to MPN. Usually found in haematopoietic progenitors and stem cells, this mutation has also been described in endothelial cells (ECs) of MPN patients. In this study, we have questioned the impact of the JAK2^V617F mutation on EC phenotype and functions. We developed an induced pluripotent stem cells strategy to compare JAK2 mutant and wild-type ECs. Transcriptomic assays showed that several genes and pathways involved in inflammation, cell adhesion and thrombotic events were over-represented in JAK2^V617F ECs and expression levels of von Willebrand factor and P-selectin (CD62P) proteins were increased. Finally, we found that leucocytes from MPN patients adhere more tightly to JAK2^V617F ECs. Our results show that JAK2^V617F ECs have a pro-inflammatory and pro-thrombotic phenotype and were functionally pro-adherent.

Keywords

BCR-ABL1-negative myeloproliferative neoplasms - JAK2^V617F mutation - thrombosis - endothelial cells - induced pluripotent stem cells

Volltext

Referenzen

References
1 James C, Ugo V, Le Couédic JP. , et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434 (7037): 1144-1148
2 Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011; 118 (07) 1723-1735
3 Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost 2014; 40 (03) 348-358
4 De Stefano V, Qi X, Betti S, Rossi E. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost 2016; 115 (02) 240-249
5 Kiladjian JJ, Cervantes F, Leebeek FW. , et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008; 111 (10) 4922-4929
6 Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 2009; 113 (21) 5246-5249
7 Rosti V, Villani L, Riboni R. , et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood 2013; 121 (02) 360-368
8 Teofili L, Martini M, Iachininoto MG. , et al. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood 2011; 117 (09) 2700-2707
9 Patsch C, Challet-Meylan L, Thoma EC. , et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol 2015; 17 (08) 994-1003
10 Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8 (01) 118-127
11 Ritchie ME, Phipson B, Wu D. , et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43 (07) e47
12 Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125 (1-2): 279-284
13 Subramanian A, Tamayo P, Mootha VK. , et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102 (43) 15545-15550
14 Mootha VK, Lindgren CM, Eriksson KF. , et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34 (03) 267-273
15 Hur J, Yoon CH, Kim HS. , et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004; 24 (02) 288-293
16 Kalogeris TJ, Baines C, Korthuis RJ. Adenosine prevents TNFα-induced decrease in endothelial mitochondrial mass via activation of eNOS-PGC-1α regulatory axis. PLoS One 2014; 9 (06) e98459
17 Favaloro EJ. Differential expression of surface antigens on activated endothelium. Immunol Cell Biol 1993; 71 (Pt 6): 571-581
18 Nieves Torres EC, Yang B, Roy B. , et al. Adventitial delivery of lentivirus-shRNA-ADAMTS-1 reduces venous stenosis formation in arteriovenous fistula. PLoS One 2014; 9 (04) e94510
19 Misra S, Lee N, Fu AA. , et al. Increased expression of a disintegrin and metalloproteinase thrombospondin 1 in thrombosed hemodialysis grafts. J Vasc Interv Radiol 2008; 19 (01) 111-119
20 Schaff M, Receveur N, Bourdon C. , et al. Novel function of tenascin-C, a matrix protein relevant to atherosclerosis, in platelet recruitment and activation under flow. Arterioscler Thromb Vasc Biol 2011; 31 (01) 117-124
21 McGee M, Wagner WD. Chondroitin sulfate anticoagulant activity is linked to water transfer: relevance to proteoglycan structure in atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23 (10) 1921-1927
22 Stojkovic S, Kaun C, Basilio J. , et al. Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation. Sci Rep 2016; 6: 25171
23 Nussbaum C, Bannenberg S, Keul P. , et al. Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial P-selectin. Nat Commun 2015; 6: 6416
24 van Hooren KW, Spijkers LJ, van Breevoort D. , et al. Sphingosine-1-phosphate receptor 3 mediates sphingosine-1-phosphate induced release of Weibel-Palade bodies from endothelial cells. PLoS One 2014; 9 (03) e91346
25 Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 571-581
26 Takata Y, Seki R, Kanajii T. , et al. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms. Kurume Med J 2014; 60 (3-4): 89-97
27 Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 2012; 481 (7381): 295-305
28 Raya A, Rodríguez-Pizà I, Guenechea G. , et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009; 460 (7251): 53-59
29 Ye Z, Zhan H, Mali P. , et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 2009; 114 (27) 5473-5480
30 Li M, Cascino P, Ummarino S, Di Ruscio A. Application of induced pluripotent stem cell technology to the study of hematological diseases. Cells 2017; 6 (01) E7
31 Gu M, Shao NY, Sa S. , et al. Patient-specific iPSC-derived endothelial cells uncover pathways that protect against pulmonary hypertension in BMPR2 mutation carriers. Cell Stem Cell 2017; 20 (04) 490-504
32 Hamauchi S, Shichinohe H, Uchino H. , et al. Cellular functions and gene and protein expression profiles in endothelial cells derived from moyamoya disease-specific iPS cells. PLoS One 2016; 11 (09) e0163561
33 Saliba J, Hamidi S, Lenglet G. , et al. Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. PLoS One 2013; 8 (09) e74257
34 Ye Z, Liu CF, Lanikova L. , et al. Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. Stem Cells 2014; 32 (01) 269-278
35 Lin CH, Kaushansky K, Zhan H. JAK2^V617F-mutant vascular niche contributes to JAK2^V617F clonal expansion in myeloproliferative neoplasms. Blood Cells Mol Dis 2016; 62: 42-48
36 Hobbs CM, Manning H, Bennett C. , et al. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood 2013; 122 (23) 3787-3797
37 Zaleskas VM, Krause DS, Lazarides K. , et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006; 1: e18
38 Lamrani L, Lacout C, Ollivier V. , et al. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Blood 2014; 124 (07) 1136-1145
39 Etheridge SL, Roh ME, Cosgrove ME. , et al. JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms. Proc Natl Acad Sci U S A 2014; 111 (06) 2295-2300
40 Rauch A, Wohner N, Christophe OD, Denis CV, Susen S, Lenting PJ. On the versatility of von Willebrand factor. Mediterr J Hematol Infect Dis 2013; 5 (01) e2013046
41 Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood 2011; 118 (26) 6743-6751
42 Gupta N, Edelmann B, Schnoeder TM. , et al. JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1. Leukemia 2017; 31 (05) 1223-1226
43 Tadmor T, Bejar J, Attias D. , et al. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms. Am J Hematol 2013; 88 (05) 355-358
44 Matsuura S, Mi R, Koupenova M. , et al. Lysyl oxidase is associated with increased thrombosis and platelet reactivity. Blood 2016; 127 (11) 1493-1501
45 Zhan H, Lin CHS, Segal Y, Kaushansky K. The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms. Leukemia 2018; 32 (02) 462-469
46 Ohneda O, Ohneda K, Arai F. , et al. ALCAM (CD166): its role in hematopoietic and endothelial development. Blood 2001; 98 (07) 2134-2142
47 Uenishi G, Theisen D, Lee JH. , et al. Tenascin C promotes hematoendothelial development and T lymphoid commitment from human pluripotent stem cells in chemically defined conditions. Stem Cell Reports 2014; 3 (06) 1073-1084
48 Nakamura-Ishizu A, Okuno Y, Omatsu Y. , et al. Extracellular matrix protein tenascin-C is required in the bone marrow microenvironment primed for hematopoietic regeneration. Blood 2012; 119 (23) 5429-5437
49 Wallace TA, VonDerLinden D, He K, Frank SJ, Sayeski PP. Microarray analyses identify JAK2 tyrosine kinase as a key mediator of ligand-independent gene expression. Am J Physiol Cell Physiol 2004; 287 (04) C981-C991

Zusatzmaterial

Supplementary Material (PDF)